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Background: Data that directly associate utilization of novel systemic therapies with survival trends in metastatic
breast cancer (MBC) are limited. In the setting of de novo MBC, large registry analyses cite positive temporal trends
in survival, but the extent to which advances in systemic therapy have contributed to these gains is not clear.
Methods: The City of Hope Cancer Registry was used to identify a consecutive series of patients with de novo MBC
who received their first line of therapy between 1985 and 2004. Comprehensive clinicopathologic and
treatment-related data were collected for each patient. Univariate analyses were conducted via Cox regression to
identify factors associated with improved survival. Multivariate analysis was also conducted via Cox regression and
the stepwise procedure was used to identify independent predictors of survival.
Results: A total of 324 patients with de novo MBC were identified. After application of exclusion criteria, including
the sole presence of supraclavicular node metastasis, 274 patients were retained in the analysis. The
treatment-related characteristics associated with improved survival included: use of endocrine therapy (hazard ratio
[HR] 0.60, 95%CI 0.47-0.77; P<0.0001), and addition of bisphosphonates (HR 0.70, 95%CI 0.52-0.96; P=0.02). However,
recipients of novel cytotoxic agents (defined as drugs approved for MBC since 1994) had no improvement in
survival relative to patients treated with older cytotoxic agents. On multivariate analysis, age (< 50), receipt of
aromatase inhibitors, and receipt of zoledronic acid were independent predictors of survival.
Conclusions: The overall survival of women with de novo metastatic breast cancer has improved over the past 20
years. However, the contribution of conventional cytotoxic agents to this improvement is minimal.
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Over the past 30 years, the survival of women with early
stage breast cancer has been prolonged [1]. In addition
to earlier detection, the use of adjuvant chemotherapy
and endocrine therapy following definitive surgery and
radiation therapy is credited with a significant improve-
ment in overall survival. However, these same systemic
therapies that prolong the survival of women with early
stage disease are only palliative in metastatic disease. For
women with metastatic HER2 positive breast cancers,* Correspondence: spal@coh.org
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reproduction in any medium, provided the orthe addition of trastuzumab to first line chemotherapy
has been shown to both prolong both the disease free
and overall survivals [2]. Shortly after the FDA approved
trastuzumab for metastatic breast cancer (MBC), an
FDA panel was convened to review the indications for
approving new agents as first-line therapy in advanced
breast cancer. The committee recommended that im-
provement in overall survival should be demonstrated
for an agent considered for the first line treatment of
advanced breast cancer [3].
Since 1994, a number of agents have been shown to be
active in advanced breast cancer. These include: pacli-
taxel, docetaxel, capecitabine, vinorelbine, gemcitabine,
nab-paclitaxel, and ixabepilone [3]. The recent debate
about the use of bevacizumab in breast cancer hasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Categorization of cytotoxic chemotherapies
received during the study period










Novel agents were considered to be those approved since 1994 and are listed
in Category B, while other available agents are included in Category A.
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interventions and to question if prolongation in overall
survival is a realistic benchmark for all new agents [4].
The goal of this study was to assess the impact of newer
chemotherapy agents on overall survival of women with
newly diagnosed de novo metastatic disease (i.e., primary
distant MBC). Several other investigators have used exist-
ing databases to determine whether advances in systemic
therapy have improved patient survival over different time
intervals [5-10]. These studies have generally included
both women who developed recurrent disease after adju-
vant chemotherapy and/or endocrine therapy and patients
treated with endocrine therapy. Using the City of Hope
Cancer Registry, we compared the overall survival of
women with de novo metastatic breast cancer treated be-
tween January 1, 1985 and December 31, 1994 with the
overall survival of women diagnosed between January 1,
1995 and December 31, 2004 with attention to the impact
of chemotherapy on disease outcome.
Methods
Patient selection
A consecutive series of patients with de novo MBC were
identified from the City of Hope (COH) Cancer Registry
through an IRB approved protocol. The registry houses
data on all patients who receive cancer treatment at the
institution. This database has been maintained for over
three decades and includes patient demographic infor-
mation and disease-related variables, including diagno-
sis, date of diagnosis, pathologic assessment, sites of
metastasis, and type/modality of treatment. Disease and
vital status are updated at least annually, and date of last
follow-up or death is recorded. Vital status is confirmed
by either cross-referencing clinician reports or the Social
Security Death Index. Patients eligible for the current
analysis were those with de novo MBC diagnosed be-
tween January 1, 1985 and December 31, 2004. For con-
sideration in the current study, patients were required to
have stage IV breast cancer as defined by the American
Joint Committee on Cancer (AJCC) Cancer Staging
Manual (6th Ed) [9]. A relevant change in this edition
was designation of ipsilateral supraclavicular node in-
volvement as N3 disease (previously considered M1 dis-
ease). Thus, patients diagnosed with stage IV disease on
the basis of ipsilateral supraclavicular node involvement
alone were excluded from analyses. Medical records for
each de novo MBC registry case was reviewed in full by
the principal investigator (S.K.P) or trained associates
(S.O.; S.W.) to ensure completeness and appropriateness
for inclusion in the current study.
Variables
Variables obtained from the registry included date of
birth, date of diagnosis, date of death or last follow-up,estrogen receptor (ER) and progesterone receptor (PR)
status, human epidermal growth factor receptor 2
(HER2) status, tumor histology, and sites of metastases.
As hormone receptor status was not reported consist-
ently by the cancer registry prior to January 1, 1995, in-
complete data were supplemented through review of
pathology records. Hormone receptor status was
assigned in the context of institutional reference ranges
for the assay utilized. HER2 status, primarily available
for patients diagnosed with breast cancer since 1998,
was also obtained from the pathology records when not
recorded in the registry. Patients were considered
HER2-positive if immunohistochemical staining for
HER2 was classified as 2+ or 3+ or the HER2/neu:
centromere 17 ratio determined by fluorescence in situ
hybridization (FISH) was ≥ 2.2. Histology was classified
as either inflammatory or non-inflammatory. Sites of
metastasis were coded as liver, lung, brain, bone, supra-
clavicular node, and soft tissue. Thorough chart review
was conducted for each patient to ascertain treatment-
related data. To stratify patients based on receipt of
older and novel cytotoxics, the most commonly used
cytotoxic agents were divided into two categories (A and
B), noted in Table 1. Endocrine therapy was segregated
into use of selective estrogen receptor modulators
(SERMs), AIs, luteinizing hormone releasing hormone
(LHRH) analogues, and fulvestrant. Patients who were
treated with lapatinib or trastuzumab were coded as re-
ceiving HER2-directed therapy. Bone-directed therapy
with intravenous bisphosphonates was coded separately
for pamidronic and zoledronic acid. To examine tem-
poral trends, the cohort was divided into two groups
based on date of diagnosis: (1) between January 1, 1985
and December 31, 1994 (Period A), and (2) between
January 1, 1995 and December 31, 2004 (Period B).
Stratification into these two time periods was predicated
on the approval of paclitaxel in 1994 – after this time,
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gained FDA approval.
Statistical analysis
Patients in each period were followed until the first of
the following occurrences: death, date of last follow-up,
or until 3 years after the end of the study period (i.e.,Table 2 Patient characteristics stratified by study period
Characteristic Period A (n= 151)*
n (%









Bone Only 37 (25
Supraclavicular Node 55 (36
















Category A** 85 (56
Category A + B 32 (21
Receipt of HER2-directed therapy 2 (1
Receipt of Bisphosphonates
Pamidronic acid 8 (5
Zoledronic acid 3 (2
Percentages reflect the proportion of patients in each subgroup relative to the tota
for ER, PR, and HER2 status. For these variables, percentages reflect the proportion
respective period for whom pathologic data is available. P-values determined using
* Period A encompasses patients diagnosed between January 1, 1985 and Decemb
1995 and December 31, 2004.
** See Table 1 for delineation of cytotoxic agents within Category A and Category BDecember 31, 2008). Univariate analyses were performed
by Cox regression to determine differences in survival for
the following comparisons: period of diagnosis (Period A
v Period B), age at diagnosis (≤ 50 v > 50), histology (in-
flammatory v invasive ductal), ER status (positive v nega-
tive), PR status (positive v negative), HER2 status




) 96 (78) 0.59
) 45 (37) 0.30
) 39 (32) 0.24
) 10 (8) 0.72
) 82 (67) 0.008
) 31 (25) 0.52
) 34 (28) 0.20
) 22 (18) 0.18
) 75 (68)
) 34 (32) 0.01
) 54 (51)
) 53 (49) 0.75
) 31 (39)
) 32 (62) 0.71
) 52 (42) 0.0002
) 46 (37) 0.72
) 5 (4) 0.87
) 19 (15) 0.86
) 15 (12)
) 95 (77) <0.0001
) 19 (15) 0.17
) 37 (30) 0.0007
) 35 (28) 0.04
l number of patients in the respective period (i.e., Period A or Period B), except
of patients in each subgroup relative to the total number of patients in the
the Chi-square test.
er 31, 1994. Period B encompasses patients diagnosed between January 1,
.
Table 3 Univariate analyses comparing survival in patient
subgroups stratified by clinicopathologic characteristics
Characteristic Hazard ratio 95%CI P-value
Date of diagnosis
Period A 1.00 reference 0.10
Period B 0.95 0.92 – 1.00
Age (years)
≤ 50 1.00 reference 0.06
> 50 1.27 1.00 – 1.63
Histology
Non-Inflammatory 1.00 reference 0.21
Inflammatory 1.22 0.88 – 1.69
ER Status
Negative 1.00 reference 0.03
Positive 0.69 0.50 – 0.96
PR Status
Negative 1.00 reference 0.17
Positive 0.8 0.59 – 1.09
HER2 Status
Negative 1.00 reference 0.08
Positive 0.55 0.28 – 1.08
Liver Mets
No 1.00 reference 0.60
Yes 1.08 0.80 – 1.44
Lung Mets
No 1.00 reference 0.10
Yes 1.25 0.95 – 1.65
Brain Mets
No 1.00 reference 0.22
Yes 1.43 0.80 – 2.56
Bone Mets
No 1.00 reference 0.06
Yes 1.29 0.98 – 1.70
Bone Only Mets
No 1.00 reference 0.23
Yes 0.83 0.62 – 1.12
Supraclavicular Node Mets
No 1.00 reference 0.56
Yes 0.92 0.69 – 1.22
Soft Tissue Mets
No 1.00 reference 0.53
Yes 1.11 0.78 – 1.59
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metastasis (yes v no), bone metastasis only (yes v no),
supraclavicular metastasis (yes v no), soft tissue metas-
tasis (yes v no), receipt of endocrine therapy (yes v no),
receipt of SERMs (yes v no), receipt of AIs (yes v no),
receipt of LHRH analogues (yes v no), receipt of fulves-
trant (yes v no), receipt of chemotherapy (yes v no),
type of chemotherapy rendered (receipt of cytotoxic
agents from Category A v Categories A and B), receipt
of HER2-directed therapy (yes v no), receipt of bispho-
sphonate therapy (yes v no), receipt of pamidronate acid
(yes v no), and receipt of zoledronic acid (yes v no).
Notably, with respect to ovarian suppression, only
pharmacologic suppression with LHRH analogues was
recorded; oophorectomy, ovarian ablation, and other
surgical techniques were not captured. Variables bearing
an association with survival with P<0.20 were incorpo-
rated in a multivariate analysis using stepwise regres-
sion. Variables with a P<0.10 were retained in the
model. To examine the a priori hypothesis that
advances in cytotoxic therapy have not resulted in cu-
mulative improvements in survival, it was decided that
the comparison of survival in patients receiving cyto-
toxic agents from Category A v Category A and B would
be retained in the multivariate model, irrespective of the
result on univariate analysis.
Results
Patient characteristics
Of 324 consecutive patients with a diagnosis of de novo
MBC, 274 are included in the analysis. Reasons for ex-
clusion included supraclavicular nodal disease only
(n=29), misclassification of recurrent disease (n=15), and
patient refusal of consent for research use of clinical in-
formation (n=6). Clinicopathologic and treatment-
related data for all patients is summarized in Table 2.
The median follow-up of survivors was 2.5 years for the
overall population.
Univariate analyses
Univariate analyses of survival by clinicopathologic pre-
dictors are presented in Table 3. Patients diagnosed dur-
ing period B had a slightly longer median survival as
compared to patients treated during period A, although
this difference was not statistically significant (3.0 years
vs 2.5 years, respectively; P=0.10). Among the clinico-
pathologic factors assessed, only ER status was signifi-
cantly associated with improved survival (hazard ratio
[HR] 0.69, 95%CI 0.50-0.96; P=0.03). On the other hand,
with treatment-related variables, multiple significant
associations with survival were observed (Table 4).
Treatment with endocrine therapy was associated with
an improvement in survival (HR=0.60, 95%CI 0.47-0.77;
P<0.0001), and within this category, treatment withSERMs, AIs, and fulvestrant were each associated with
improvements in survival (P=0.007, P<0.0001, and
P=0.0004, respectively). Although receipt of chemotherapy
approached significance as a predictor of survival (HR
Table 5 Multivariate analysis comparing survival in
subgroups of patients with de novo MBC stratified by
both clinicopathologic and treatment-related
characteristics
Characteristic Hazard ratio 95% CI P-value
Category
A 1.00 reference 0.76
A + B 1.04 0.77 – 1.40
Age
<50 1.00 reference 0.0008
≥50 1.61 1.23 – 2.20
AI
No 1.00 reference 0.0008
Yes 0.50 0.34 – 0.75
Zoledronic acid
No 1.00 reference 0.005
Yes 0.45 0.26 – 0.79
Table 4 Univariate analyses comparing survival in patient
groups stratified by treatment-related characteristics
Characteristic Hazard ratio 95%CI P-value
Endocrine Therapy
No 1.00 reference <0.0001
Any 0.60 0.47 – 0.77
SERM
No 1.00 reference 0.007
Yes 0.63 0.48 – 0.82
AI
No 1.00 reference <.0001
Yes 0.47 0.34 – 0.66
LHRH
No 1.00 reference 0.75
Yes 0.85 0.31 – 2.30
Fulvestrant
No 1.00 reference 0.0004
Yes 0.29 0.15 – 0.57
Chemotherapy
No 1.00 reference 0.06
Yes 0.76 0.57 – 1.02
Category
A 1.00 reference
A+B 0.8 0.60 – 1.07 0.13
HER2-Directed Therapy
No 1.00 reference 0.15
Yes 0.69 0.41 – 1.14
Bisphosphonate Therapy
No 1.00 reference 0.02
Yes 0.70 0.52 – 0.96
Pamidronic acid
No 1.00 reference 0.44
Yes 0.87 0.62 – 1.23
Zoledronic acid
No 1.00 reference 0.002
Yes 0.50 0.32 – 0.77
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difference in survival among patients who received agents
exclusively from Category A as opposed to both Category
A and B (P=0.13). In the current analysis, patients receiv-
ing HER2-directed agents comprised a relatively small
subset (n=21), challenging inferences in this subset. Lastly,
bisphosphonate therapy was associated with improved
survival (HR 0.70, 95%CI 0.52-0.96; P=0.02), and within
this category, receipt of zoledronic acid was associated
with the same (HR 0.50, 95%CI 0.32-0.77; P=0.002).Stepwise multivariate analysis
In order to account for the possible confounding issues,
the estimator for the variable of interest (Category A v
[Category A and B]) was examined. A model with all the
terms was created and then each variable was taken out
and the variable of interest’s estimator was evaluated. Ul-
timately age, receipt of AI, and receipt of zoledronic acid
were found to be independent significant predictors of
survival; while category (i.e., Category A v [Category A +
B]) was not. The adjusted variables are listed in order of
significance in Table 5.Discussion
The impact of systemic therapy on the survival of
women with metastatic breast cancer over time has been
addressed by seven different investigators and these
results are summarized in Table 6. All studies suggest
that modest improvements in overall survival have been
observed in recent years. An improvement in overall
survival advantage is most pronounced in the trials
where a higher percentage of women have hormone
receptor-positive disease. We also observed a survival
advantage for women with hormone receptor-positive
disease and those who received an aromatase inhibitor.
These observations are consistent with the published lit-
erature which demonstrates that a third generation aro-
matase inhibitor prolongs the survival of women with
MBC compared with a progestational agent [11,12].
The Hellenic Trialists compared the overall survival
for women enrolled in 10 different treatment trials for
MBC over a 15 year time interval and reported improv-
ing survivals over time [7]. This Greek series is con-
founded by the inclusion of women on trastuzumab-
Table 6 Summary of trials addressing systemic therapy in advanced breast cancer
Author, year Institution(s)/ Database Population Time intervals Comments
Andre, 2004 [5] France (3 institutions) 724 women de novo
metastatic breast cancer
1987-1993 Excluded supraclavicular
lymph node only patients.
Improved 3 year overall
survival (OS; 44% vs 27%)
was seen in the more
recent time period.
1994-2000
Giordano, 2004 [9] MD Anderson
Cancer Center
834 women with recurrence
after adjuvant doxorubicin











Chia, 2007 [6] British Columbia
Cancer Agency
2150 women with both recurrent and
de novo metastatic breast cancer
1991-1992 An improvement in
overall survival was noted
over time, primarily in





Dawood, 2008 [13] Surveillance, Epidemiology, and
End Results Registry
15,438 women with both recurrent and
de novo metastatic breast cancer











Dafni, 2009 [14] Hellenic Cooperative Group 1361 enrolled on trials for
treatment of recurrent and
de novo metastatic breast cancer
1991-1994 Trastuzumab used in
24% and 30% of patients






Netherlands 8031 women with both recurrent and
de novo metastatic breast cancer






Pal, 2011 City of Hope 274 de novo metastatic
breast cancer only
1985-1994 Overall survival improved
for those receiving
endocrine therapy,
but no apparent overall
survival benefit with newer
chemotherapeutic agents.
1995-2004
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questionably associated with an improved overall sur-
vival. In our series, the number of women receiving
trastuzumab-containing chemotherapy was too small to
demonstrate a survival advantage.
In our study and that of Andre, the trials included only
patients who presented with de novo metastatic disease
and reported an overall improvement in survival [5].
However, the survival advantage was largely attributed
to benefits from endocrine therapy. We found no advan-
tage to the use of the newer chemotherapeutic agents
and Andre found no survival advantage for women with
hormone receptor-negative disease [5].
We uniquely identified that the use of intravenous
zoledronate was predictive of an improved survival.
Given the lack of data supporting a survival advantage
for bone-directed therapies in metastatic disease, wehypothesize that the improved survival observed is indi-
cative of improved palliative care.
All the published series are retrospective reviews and
the results are confounded by improvements in radio-
logic imaging, changes in the staging system, and poten-
tial for lead time bias. Some of the series included
women with locally recurrent disease, a pattern of recur-
rence that is associated with a more favorable outcome.
Only our study and that of Andre included only patients
with de novo metastatic disease [5]. It remains uncertain
if the natural history of de novo metastatic disease differs
meaningfully from recurrent disease after treatment of
early stage cancer. We are currently reviewing the out-
come using the same analysis employed here to assess
the impact of newer systemic therapy in women with re-
current MBC. We anticipate that this will provide add-
itional hypothesis-generating data.
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In reviewing the available literature, it appears that
advances in endocrine therapy and trastuzumab are
largely responsible for overall survival improvements in
the treatment of metastatic breast cancer. Improvements
in endocrine therapy and the use of trastuzumab appear
to have improved the survival of women with advanced
breast cancer. The impact of conventional chemotherapy
on survival appears to be minimal in the context of our
retrospective cohort; perhaps these findings warrant
more definitive exploration through the formation of
multi-institution databases. These multi-institutional
databases should include ideally include the same granu-
larity of data as in our analysis and other, and should
also capture surgical and radiation data to infer the ben-
efits rendered from these modalities. Findings from such
efforts could surely supplant the existent studies which
draw from limited single-institution experiences.
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